Table 4

Study 203

Mean (X) and Mean Change (∆) from Baseline in 28-item HAMD

LAST OBSERVATION CARRIED FORWARD ANALYSIS

Treatment

Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

120

31.5

113

-4.7

120

-8.2

120

-11.3

120

-12.4

120

-13.0

120

-13.2

120

-13.9

120

-14.1

BUP SR 300 (II)

113

32.2

113

-4.9

113

-8.2

113

-10.9

113

-12.1

113

-12.8

113

-13.5

113

-13.9

113

-14.5

Placebo (P)

117

32.2

116

-4.7

117

-7.6

117

-9.1

117

-10.1

117

-10.9

117

-11.2

117

-11.5

117

-11.8

2-sided p-values for pairwise comparisons

I. vs. P

>0.2

0.98

0.48

0.042

0.051

0.10

0.11

0.069

0.088

II vs. P

>0.5

0.77

0.56

0.10

0.093

0.13

0.0077

0.0072

0.051

OBSERVED CASES ANALYSIS

Treatment

Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

120

31.5

113

-4.7

109

-8.6

98

-12.1

89

-14.2

83

-15.6

70

-17.0

67

-18.6

64

-19.3

BUP SR 300 (II)

113

32.2

113

-4.9

100

-8.4

98

-11.7

87

-13.7

77

-15.2

74

-17.4

69

-18.4

62

-20.3

Placebo (P)

117

32.2

116

-4.7

112

-7.7

102

-10.0

91

-11.6

75

-13.4

69

-16.2

64

-17.6

56

-18.1

2-sided p-values for pairwise comparisons

I. vs. P

>0.2

0.98

0.35

0.072

0.050

0.153

0.41

0.29

0.24

II vs. P

>0.5

0.77

0.47

0.14

0.11

0.31

0.47

0.48

0.16